Abstract | OBJECTIVES: METHODS: RESULTS: The rates of premature discontinuation of ticlopidine (SES group <3 months: 11%, BMS group <1 month: 11%, p = NS) and stent thrombosis (SES group: 1%, BMS group: 0%, p = NS) were similar in the two groups. At follow-up, restenosis rate and target vessel revascularization rate were lower in the SES group(4% vs 19%, p < 0.001 and 4% vs 10%, p = 0.149, respectively). Furthermore, the occurrence of MACE at 270 days was significantly less frequent in the SES group compared with the BMS group (6% vs. 17%, p = 0.038). Multivariate analysis showed SES use tended to predict 270-day MACE (hazard ratio 0.37, 95% confidence interval 0.14-1.02, p = 0.055). Culprit lesion located in the left main trunk was identified as an independent predictor of 270-day MACE (hazard ratio 5.43, 95% confidence interval 1.07-27.59, p = 0.041). CONCLUSIONS: The use of a SES was not associated with increased risk of stent thrombosis compared with a BMS. With lower rates of restenosis and subsequent target vessel revascularization, SES placement could provide superior outcomes in patients with acute myocardial infarction.
|
Authors | Tomoko Gochi, Hisashi Umeda, Naoki Yoshida, Hironobu Maekawa, Kosuke Watanabe, Taro Okada, Toshiaki Katoh, Toru Asai, Tomomitsu Tani, Masaki Yokoya, Yoshimasa Murakami, Toyoaki Matsushita, Takeshi Shimizu, Yukio Ozaki, Shinya Hiramitsu, Toyoaki Murohara, Masanori Nomura, Shinichiro Morimoto, Hitoshi Hishida |
Journal | Journal of cardiology
(J Cardiol)
Vol. 48
Issue 5
Pg. 253-61
(Nov 2006)
ISSN: 0914-5087 [Print] Netherlands |
PMID | 17136820
(Publication Type: Comparative Study, English Abstract, Journal Article)
|
Chemical References |
- Platelet Aggregation Inhibitors
- Ticlopidine
- Sirolimus
|
Topics |
- Aged
- Coronary Restenosis
(prevention & control)
- Female
- Humans
- Male
- Middle Aged
- Myocardial Infarction
(therapy)
- Platelet Aggregation Inhibitors
(administration & dosage)
- Retrospective Studies
- Sirolimus
(administration & dosage)
- Stents
(adverse effects)
- Ticlopidine
(administration & dosage)
- Treatment Outcome
|